|
Synonyms: BAN-2401 | BAN2401 | lecanemab-irmb | Leqembi®
lecanemab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that targets amyloid β protein (APP) protofibrils [1,7]. It binds more potently to amyloid β protofibrils than to monomeric amyloid β [1,6]. Lecanemab was developed by Eisai and Biogen for potential to slow neurological decline in patients in the very early stages of developing Alzheimer's disease. It is not suitable for other forms of dementia.
This blog post by Derek Lowe ('Lecanemab and Alzheimer's: More Data'; posted on Nov. 30, 2022) provides a sound review of lecanemab's reported efficacy [8], what it contributes as an Alzheimer's therapy, and the issues around potential lecanemab-mediated cerebral bleeding events. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2023)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11194 | lecanemab |
| Synonyms |
| BAN-2401 | BAN2401 | lecanemab-irmb | Leqembi® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1016 |
| Other databases | |
| GtoPdb PubChem SID | 472319322 |
| Search PubMed clinical trials | lecanemab |
| Search PubMed titles | lecanemab |
| Search PubMed titles/abstracts | lecanemab |
